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1. INTRODUCTION {#mgg3962-sec-0005}
===============

Maturity‐onset diabetes of the young (MODY) (OMIM \#606391) is characterized by defects in insulin secretion, autosomal dominant inheritance, early hyperglycemia onset, and negative anti‐beta cell antibodies (Fajans & Bell, [2011](#mgg3962-bib-0026){ref-type="ref"}; Fajans, Bell, & Polonsky, [2001](#mgg3962-bib-0027){ref-type="ref"}; McDonald et al., [2011](#mgg3962-bib-0055){ref-type="ref"}; Vaxillaire & Froguel, [2008](#mgg3962-bib-0093){ref-type="ref"}). To date, mutations in 11 genes have been frequently associated with MODY, some of which have recently been described (Bonnefond et al., [2012](#mgg3962-bib-0008){ref-type="ref"}; Bowman et al., [2012](#mgg3962-bib-0010){ref-type="ref"}; Prudente et al., [2015](#mgg3962-bib-0068){ref-type="ref"}). Few cases, however, have been associated with the *KLF11*, *PAX4*, and *BLK*, and the validity of their association with the MODY phenotype is currently questioned (Flannick et al., [2013](#mgg3962-bib-0028){ref-type="ref"}; Sanyoura, Philipson, & Naylor, [2018](#mgg3962-bib-0082){ref-type="ref"}). Definitive diagnosis relies on genetic tests, traditionally by Sanger sequencing (Sanger & Coulson, [1975](#mgg3962-bib-0080){ref-type="ref"}). However, given the genetic heterogeneity of this condition and the difficulty related to studying some genes due to their large size or lack of hotspots, next‐generation sequencing (NGS) seems promising for a cost‐effective genetic analysis upon clinical suspicion of MODY (American Diabetes Association, [2017](#mgg3962-bib-0002){ref-type="ref"}; Colclough, Saint‐Martin, Timsit, Ellard, & Bellanné‐Chantelot, [2014](#mgg3962-bib-0015){ref-type="ref"}). In Brazil, few cohorts have been screened for MODY, and all of them have been conducted using a candidate gene approach (mainly *GCK*/*HNF1A*) with a high prevalence of MODY‐X (unclear genetic diagnosis---46.2%--73.9%) (Furuzawa et al., [2008](#mgg3962-bib-0033){ref-type="ref"}; Giuffrida et al., [2017](#mgg3962-bib-0037){ref-type="ref"}; Maraschin et al., [2008](#mgg3962-bib-0054){ref-type="ref"}; Moises et al., [2001](#mgg3962-bib-0059){ref-type="ref"}; Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"}), which could be explained by genes that are more rarely associated with MODY. The objective of this study was to use an NGS target panel (tNGS) to investigate a Brazilian cohort of MODY patients with negative prior genetic analysis by Sanger sequencing or Multiplex ligation ‐dependent probe amplification (MLPA).

2. MATERIALS AND METHODS {#mgg3962-sec-0006}
========================

2.1. Subjects {#mgg3962-sec-0007}
-------------

Starting with a single‐gene approach previously published (Dotto et al., [2019](#mgg3962-bib-0019){ref-type="ref"}; Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"}) for three MODY subtypes: *GCK* (MODY‐*GCK*) (OMIM \#125851) or *HNF1A* (OMIM \#600496)/*HNF1B* (OMIM \#137920) (MODY non‐*GCK*) (Figure [1](#mgg3962-fig-0001){ref-type="fig"} and supplemental material, cohort selection and data analysis), 102 patients with negative prior genetic analysis were selected for this targeted NGS study.

![Flowchart of the study cohort selection. To select candidates for tNGS, we performed an initial genetic screening in 198 probands for 3 MODY subtypes, namely, *GCK, HNF1A*, and *HNF1B*. This candidate gene approach has been guided using clinical laboratory characteristics specific to each phenotype. Only 1 gene was investigated per patient, using Sanger sequencing (*GCK* OR *HNF1A*) OR MLPA (*HNF1B*). The cohort described in the current study is composed of patients who did not present any candidate variant in this initial approach (*GCK, HNF1A, HNF1B*) and were selected for tNGS. \*Minimum inclusion criteria: Available in Supplemental Material ‐ Cohort Selection and Data Analysis; ¥ Number of patients presenting pathogenic / likely pathogenic variants](MGG3-7-e962-g001){#mgg3962-fig-0001}

All the subjects were referred to the Monogenic Diabetes Group, School of Medicine, University of Sao Paulo (USP) using electronic forms (available at <http://www.diabetesgeneticousp.com>) or directly by the medical centers or universities from all regions of Brazil. The patients and/or legal guardians provided written informed consent.

2.2. Library preparation and sequencing {#mgg3962-sec-0008}
---------------------------------------

Samples from the 102 selected patients were subjected to genomic quality and integrity control (Bioanalyzer, Agilent Technologies) as well as DNA shearing (Covaris) prior to the enrichment protocol. The full region (upstream, exons, and introns) of 11 previously described genes frequently associated with MODY (*HNF4A*, *GCK*, *HNF1A*, *PDX1*, *HNF1B*, *NEUROD1*, *CEL*, *INS*, *ABCC8*, *KCNJ11*, and *APPL1*) was captured and enriched using a custom genetic panel (SureSelect XT, Agilent Technologies). Paired‐end sequencing was performed in a sequencing‐by‐synthesis assay (MiSeq System, Illumina). The manufacturer\'s instructions were followed in all steps.

2.3. Bioinformatics analysis {#mgg3962-sec-0009}
----------------------------

Each step performed and the programs used during preliminary processing, genomic mapping, variant calling, and annotation of the sequencing data are detailed in the supplemental material---cohort selection and data analysis.

2.4. Variant filtering workflow and pathogenicity interpretation {#mgg3962-sec-0010}
----------------------------------------------------------------

A prioritization process was applied to reduce the list of candidate variants for association with MODY. The allele frequency was evaluated using a public consortium and a local genomic database, namely, gnomAD (Lek et al., [2016](#mgg3962-bib-0047){ref-type="ref"}) and ABraOM (Naslavsky et al., [2017](#mgg3962-bib-0062){ref-type="ref"}), respectively. In addition to minor allele frequency \< 1%, each final candidate variant was evaluated in relation to the MODY estimated frequency (0.01%) (Shields et al., [2010](#mgg3962-bib-0085){ref-type="ref"}). This step was performed later to avoid exclusion of variants with border frequency in the initial filtering process. We interpreted the pathogenicity of each candidate variant according to the British Society for Genetic Medicine recommendations (Wallis et al., [2013](#mgg3962-bib-0094){ref-type="ref"}) and the American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) guidelines (Richards et al., [2015](#mgg3962-bib-0075){ref-type="ref"}). To support familial cosegregation analysis, a mathematical model (Jarvik & Browning, [2016](#mgg3962-bib-0042){ref-type="ref"}) was added to the ACMG/AMP ranking, allowing for the statistical quantification of familial aggregation data.

The location of each candidate variant was verified in the patients\' binary alignment map file (BAM) using the Integrative Genomics Viewer (IGV) (Robinson et al., [2011](#mgg3962-bib-0077){ref-type="ref"}). Sanger sequencing was performed as a confirmatory method. The details of the filtering workflow and pathogenicity interpretation are presented in the supplemental materials---cohort selection and data analysis.

3. RESULTS {#mgg3962-sec-0011}
==========

3.1. Subjects {#mgg3962-sec-0012}
-------------

One hundred and two patients with a negative prior genetic analysis were selected for target NGS. Twenty‐six of these had an initial clinical suspicion of MODY‐*GCK* and 76 of non‐*GCK* MODY. The cohort was composed of 37.3% males. The clinical and laboratory data at the first evaluation are presented in Table [1](#mgg3962-tbl-0001){ref-type="table"}.

###### 

Clinical and laboratory data for the cohort at the first evaluation

                                                                                         Median (1st \| 3rd quartile)[f](#mgg3962-note-0008){ref-type="fn"} or Percentage[g](#mgg3962-note-0009){ref-type="fn"}
  -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Age at diagnosis of diabetes or MFH[a](#mgg3962-note-0003){ref-type="fn"} (years)      20 (14 \| 27.7)
  Fasting plasma glucose (mg/dL)                                                         131 (104 \| 213)
  A1C (%)                                                                                7.5 (6.0 \| 9.2)
  Glucose tolerance test (GTT) increment[b](#mgg3962-note-0004){ref-type="fn"} (mg/dL)   109 (102 \| 115)
  Fasting C‐peptide[c](#mgg3962-note-0005){ref-type="fn"} (ng/mL)                        1.7 (1.2 \| 2.5)
  Referred weight at diagnosis[d](#mgg3962-note-0006){ref-type="fn"}                     14%‐low \| 70%‐normal \| 13%‐overweight \| 3%‐obesity
  Family history of diabetes/MFH                                                         94%‐positive \| 5%‐negative \| 1%‐unknown
  Treatment at diagnosis                                                                 24%‐diet \| 38%‐OHA[h](#mgg3962-note-0010){ref-type="fn"} \| 38%‐insulin
  Microvascular complications[e](#mgg3962-note-0007){ref-type="fn"}                      26%‐Retinopathy \| 27%‐Microalbuminuria

Normal range: Fasting plasma glucose (hexokinase) 70--99 mg/dL; A1C (HPLC) 4.1%--6.0%; Fasting C‐peptide (chemiluminescence) 1.1--4.4 ng/mL; Microalbuminuria (immunoturbidimetry) \<14.0 mg/L; Glucose tolerance test (hexokinase) 0 min 70--99 mg/dL \| 120 min \< 140 mg/dL.

MFH: mild fasting hyperglycemia.

2 hr glucose‐fasting glucose (25 patients screened).

Fasting C‐peptide: 3 years after diagnosis.

Reported by the patient ("referred weight").

Microvascular complications: Retinopathy (77 patients screened), Microalbuminuria (87 patients screened).

Continuous variables.

Discrete variables.

OHA: oral hypoglycemic agent.

John Wiley & Sons, Ltd

3.2. Sequencing metrics {#mgg3962-sec-0013}
-----------------------

Table [S1](#mgg3962-sup-0001){ref-type="supplementary-material"} summarizes the sequencing metrics, presenting data such as the number of reads obtained, the number of sequenced bases, and the target region coverage (%\>10X, %\>20X, and %\>30X).

3.3. Genetic analysis {#mgg3962-sec-0014}
---------------------

An average of 500 nonreference alleles per patient were identified during the variant calling protocol. After applying the prioritization criteria, 35/102 patients (34%) had at least one candidate variant, with one patient having two candidate variants in two different genes (Tables [2](#mgg3962-tbl-0002){ref-type="table"}, [3](#mgg3962-tbl-0003){ref-type="table"}, and Table [S2](#mgg3962-sup-0002){ref-type="supplementary-material"}).

###### 

Clinical, laboratory, and genetic characteristics of MODY probands with candidate variants

  Proband/Variant[\*](#mgg3962-note-0012){ref-type="fn"}   S.G approach    Age at diagnosis of diabetes or MFH^a^/age at genetic testing (years)   Referred weight at diagnosis^b^   Family history of diabetes/MFH (G/S/HT)^c^   Treatment at diagnosis   Current treatment        Range of FPG^d^ (mg/dL) follow‐up   Range of A1C^e^ (%)follow‐up   C‐peptide^f^ (ng/mL) follow‐up   Mic.C
  -------------------------------------------------------- --------------- ----------------------------------------------------------------------- --------------------------------- -------------------------------------------- ------------------------ ------------------------ ----------------------------------- ------------------------------ -------------------------------- -------
  *HNF4A*‐1/p.Ser3Gly^k^                                   *HNF1A* ^s^     8/14                                                                    Normal                            1/NA/NA                                      Insulin                  Insulin + Metformin      82--140                             6.8--9.0                       1.2                              No
  *HNF4A*‐2/p.His49Tyr^k^                                  *HNF1A* ^s^     17/37                                                                   Normal                            2/4/1                                        Insulin + Sulfonylurea   OHAs                     70--87                              5.3--7.3                       0.8                              No
  *HNF4A*‐3/p.Ile441Val^i^                                 *HNF1A* ^s^     16/51                                                                   Normal                            3/NA/NA                                      Sulfonylurea             Insulin + OHAs           79--260                             5.1--9.2                       2.6                              R
  *GCK‐*1/p.Val182Met^g^                                   *HNF1A* ^s^     8/19                                                                    Low                               2/5/1                                        Sulfonylurea             Diet                     89--176                             6.0--8.2                       2.1                              No
  *GCK*‐2/p.Leu185Gln^h^                                   *HNF1A* ^s^     22/28                                                                   Normal                            3/NA/NA                                      Metformin                Sulfonylurea             102--141                            6.4--8.7                       1.7                              No
  *GCK‐*3/p. Ala208Pro^h^                                  *HNF1A* ^s^     12/32                                                                   Normal                            NA/NA/NA                                     Insulin                  Diet                     128--138                            7.1--7.4                       3.0                              NA
  *GCK‐*4/p.Met235Val^g^                                   *HNF1A* ^s^     10/16                                                                   Normal                            3/5/2                                        Insulin                  Diet                     73--139                             6.6--7.2                       2.5                              No
  *GCK‐*5/p.Gly318Arg^g^                                   *GCK* ^s^       14/18                                                                   Low                               3/5/1                                        Insulin                  Diet                     87--139                             5.9--6.5                       1.7                              No
  *GCK‐*6/p.Gly318Arg^g^                                   *GCK* ^s^       35/46                                                                   Normal                            2/6/6                                        Insulin                  Diet                     110--146                            5.4--6.0                       1.3                              No
  *GCK‐*7/p.Thr326Pro^g^                                   *GCK* ^s^       28/54                                                                   Normal                            3/4/3                                        Diet                     Diet                     89--112                             5.9--6.6                       3.0                              No
  *GCK‐*8/p.ArgR447Lfs^\*^2^g^                             *GCK* ^s^       15/21                                                                   Normal                            3/4/2                                        Diet                     Diet                     117--122                            5.9--6.2                       1.6                              No
  *HNF1A*‐1/p.His505Asn^k^                                 *HNF1A* ^s^     17/43                                                                   Normal                            3/3/1                                        Diet                     OHAs                     111--219                            6.2--7.5                       2.9                              No
  *PDX1‐1*/p.Pro63Argfs^\*^60^g^                           *HNF1A* ^s^     14/53                                                                   Normal                            3/6/1                                        Insulin                  Insulin + Sulfonylurea   83--441                             6.8--9.2                       1.4                              R
  *PDX1‐2*/p.Glu222Lys^k^                                  *HNF1A* ^s^     27/38                                                                   Normal                            3/NA/NA                                      Insulin + Metformin      Insulin + Metformin      58--193                             8.5--9.7                       1.1                              No
  *HNF1B*‐1/p.Val61Gly^i^                                  *HNF1A* ^s^     25/39                                                                   Normal                            2/NA/NA                                      Insulin                  Insulin + Sulfonylurea   500‐NA                              5.5--8.8                       2.4                              No
  *HNF1B*‐2/p.Gly76Cys^k^                                  *HNF1A* ^s^     34/44                                                                   Normal                            2/NA/NA                                      Metformin                OHAs                     100--167                            5.7--7.4                       2.2                              No
  *HNF1B*‐3/p.Ser148Leu^g^                                 *HNF1B* ^m^     12/17                                                                   NA                                2/NA/NA                                      Insulin                  Insulin                  75--153                             6.1--10.0                      NA                               No
  *HNF1B*‐4/p.Arg295His^h^                                 *HNF1A* ^s^     12/20                                                                   Normal                            1/1/1                                        Diet                     DPP4i                    88--120                             5.7--6.8                       2.4                              No
  *NEUROD1*‐1/p.Tyr231Ter^g^                               *HNF1A* ^s^     20/47                                                                   Normal                            2/3/0                                        Sulfonylurea             OHAs                     137--NA                             6.1--10.0                      1.6                              No
  *CEL*‐1/p.Ala24Val^k^                                    *HNF1A* ^s^     12/17                                                                   Overweight                        3/NA/NA                                      Diet                     Sulfonylurea             113--126                            6.1--6.3                       2.6                              No
  *CEL*‐2/p.Asp102Ala^k^                                   *GCK* ^s^       5/13                                                                    Normal                            3/13/5                                       Diet                     Diet                     96--108                             5.5--6.1                       1.5                              M
  *CEL*‐3/p.Val161Met^k^                                   *HNF1A* ^s^     27/32                                                                   Normal                            3/NA/NA                                      OHAs                     Sulfonylurea             120--400                            6.6--11.8                      2.1                              No
  *CEL*‐4/p.Pro718Thr^j^                                   *HNF1A* ^s^     30/34                                                                   Obesity                           3/NA/NA                                      OHAs                     Insulin + OHAs           89--321                             5.8--12.5                      NA                               No
  *INS*‐1/p.Arg6His^k^                                     *HNF1A* ^s^     19/61                                                                   Low                               2/NA/NA                                      Sulfonylurea             Insulin + OHAs           106--360                            10.4--13.6                     2.6                              R/M
  *INS*‐2/p.Ala23Glnfs^\*^3^g^                             *HNF1A* ^s^     22/57                                                                   NA                                2/NA/NA                                      OHAs                     Insulin + OHAs           89--255                             6.3--9.7                       1.9                              R/M
  *INS*‐3/p.Ser76Asn^j^                                    *HNF1A* ^s^     30/39                                                                   Overweight                        3/NA/NA                                      OHAs                     Insulin + Metformin      65--230                             7.8--9.8                       1.1                              No
  *ABCC8*‐1/p.Ser53Cys^k^                                  *HNF1A* ^s^     30/39                                                                   Low                               3/NA/NA                                      Metformin                Diet                     117--130                            6.4--6.9                       1.0                              No
  *ABCC8*‐2/p.Ala235Thr^j^                                 *HNF1A* ^s^     34/53                                                                   Normal                            2/3/1                                        OHAs                     Insulin                  68--202                             6.2--8.1                       NA                               R/M
  *ABCC8*‐3/p.Val563Asp^k^                                 *HNF1A* ^s^     12/50                                                                   NA                                3/NA/NA                                      Sulfonylurea             Insulin                  54--697                             6.8--10.8                      3.8                              R/M
  *ABCC8*‐4/p.Gly658Val^k^                                 *HNF1A* ^s^     12/43                                                                   NA                                3/NA/NA                                      Insulin                  Insulin                  143--158                            6.0--6.4                       1.1                              No
  *ABCC8*‐5/p.Asp673Asn^k^                                 *HNF1A* ^s^     14/27                                                                   Normal                            3/1/0                                        Insulin                  Sulfonylurea             67--270                             6.0--13.7                      NA                               No
  *ABCC8*‐6/p.Arg825Trp^g^                                 *HNF1A* ^s^     21/52                                                                   Low                               3/6/4                                        Sulfonylurea             Sulfonylurea             90--271                             6.3--8.4                       2.3                              R/M
  *ABCC8*‐7/p.Leu1147Arg^k^                                *HNF1B* ^s,m^   17/51                                                                   NA                                1/NA/NA                                      Insulin                  Insulin                  45--234                             5.1--7.6                       0.4                              M
  *KCNJ11*‐1/p.Ala96Thr^k^                                 *HNF1A* ^s^     20/49                                                                   Normal                            4/6/4                                        Insulin                  Insulin + OHAs           86--258                             6.4--9.4                       1.4                              No
  D1/^¢^p.Lys266Glu^k^ + ^¥^p.Ser1018Leu^k^                *HNF1A* ^s^     11/17                                                                   Normal                            3/NA/NA                                      Metformin                Diet                     93--177                             5.5--7.2                       3.2                              NA

Normal range: FPG (hexokinase) 70--99 mg/dL; A1C (HPLC) 4.1%--6.0%; Fasting C‐peptide (chemiluminescence) 1.1--4.4 ng/mL; Microalbuminuria (immunoturbidimetry) \<14.0 mg/L.

RefSeq reference transcript: NM_175914.3 (*HNF4A*)/NM_000162.3 (*GCK*)/NM_000545.6 (*HNF1A*)/NM_000209.3 (*PDX1*)/NM_000458.2 (*HNF1B*)/NM_002500.3 (*NEUROD1*)/NM_001807.3 (*CEL*)/NM_000207.2 (*INS*)/NM_000352.3 (*ABCC8*)/NM_000525.3 (*KCNJ11*); S.G approach: Single‐gene approach (^s^ Sanger sequencing/^m^ MLPA); ^a^MFH: mild fasting hyperglycemia; ^b^Reported by the patient ("referred weight"); ^c^Familial history (without proband)--G: generations, S: patients screened, HT: heterozygous patients for the family variant; ^d^FPG: fasting plasma glucose; ^e^A1C: Glycated hemoglobin; ^f^Fasting C‐peptide: 3 years after diagnosis; Mic.C: Microvascular complications (R‐Retinopathy, M‐Microalbuminuria); ACMG five‐tier system: ^g^P (Pathogenic), ^h^L.P (Likely pathogenic), ^i^B (Benign), ^j^L.B (Likely benign), ^k^U.S (Uncertain significance); ^¢^ CEL; ^¥^ *ABCC8*; NA: not available; OHAs: more than one oral hypoglycemic agent (other than sulfonylurea).

John Wiley & Sons, Ltd

###### 

Allelic candidate variants identified using a gene panel in MODY probands with a negative prior genetic analysis

  Gene               Nucleotide change[a](#mgg3962-note-0013){ref-type="fn"}   Aminoacid change[a](#mgg3962-note-0013){ref-type="fn"}   Region             Proband (s)   ACMG[b](#mgg3962-note-0014){ref-type="fn"}                                                                   Reference (first report)
  ------------------ --------------------------------------------------------- -------------------------------------------------------- ------------------ ------------- ------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------
  *HNF4A*            c.7A \> G                                                 p.Ser3Gly                                                Exon 1             *HNF4A*‐1     U.S                                                                                                          This study[c](#mgg3962-note-0015){ref-type="fn"}
  c.145C \> T        p.His49Tyr                                                Exon 2                                                   *HNF4A*‐2          U.S           This study                                                                                                   
  c.1321A \> G       p.Ile441Val                                               Exon 10                                                  *HNF4A*‐3          B             Malecki et al. ([1999](#mgg3962-bib-0052){ref-type="ref"})                                                   
  GCK                c\. 544G \> A                                             p.Val182Met                                              Exon 5             *GCK*‐1       P                                                                                                            Froguel et al. ([1993](#mgg3962-bib-0031){ref-type="ref"})
  c.554T \> A        p.Leu185Gln                                               Exon 5                                                   *GCK*‐2            L.P           This study                                                                                                   
  c.622G \> C        p\. Ala208Pro                                             Exon 6                                                   *GCK*‐3            L.P           Garin et al. ([2008](#mgg3962-bib-0036){ref-type="ref"})                                                     
  c.703A \> G        p.Met235Val                                               Exon 7                                                   *GCK*‐4            P             García‐Herrero et al. ([2007](#mgg3962-bib-0034){ref-type="ref"})                                            
  c.952G \> A        p.Gly318Arg                                               Exon 8                                                   *GCK*‐5, *GCK*‐6   P             Pruhova et al. ([2003](#mgg3962-bib-0069){ref-type="ref"})                                                   
  c.976A \> C        p.Thr326Pro                                               Exon 8                                                   *GCK*‐7            P             Lorini et al. ([2009](#mgg3962-bib-0050){ref-type="ref"})                                                    
  c.1340_1368del29   p.ArgR447Lfs\*2                                           Exon 10                                                  *GCK*‐8            P             Ziemssen, Bellanné‐Chantelot, Osterhoff, Schatz, and Pfeiffer, ([2002](#mgg3962-bib-0098){ref-type="ref"})   
  *HNF1A*            c.1513C \> A                                              p.His505Asn                                              Exon 8             *HNF1A*‐1     U.S                                                                                                          Bellanne‐Chantelot et al. ([2008](#mgg3962-bib-0003){ref-type="ref"})
  *PDX1*             c.188delC                                                 p.Pro63Argfs\*60                                         Exon 1             *PDX1*‐1      P                                                                                                            Stoffers, Ferrer, Clarke, and Habener ([1997](#mgg3962-bib-0088){ref-type="ref"})
  c.664G \> A        p.Glu222Lys                                               Exon 2                                                   *PDX1*‐2           U.S           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  *HNF1B*            c.182T \> G                                               p.Val61Gly                                               Exon 1             *HNF1B*‐1     B                                                                                                            Edghill, ([2005](#mgg3962-bib-0020){ref-type="ref"})
  c.226G \> T        p.Gly76Cys                                                Exon 1                                                   *HNF1B*‐2          U.S           Bellanne‐Chantelot et al. ([2005](#mgg3962-bib-0005){ref-type="ref"})                                        
  c.443C \> T        p.Ser148Leu                                               Exon 2                                                   *HNF1B*‐3          P             Edghill ([2005](#mgg3962-bib-0020){ref-type="ref"})                                                          
  c.884G \> A        p.Arg295His                                               Exon 4                                                   *HNF1B*‐4          L.P           Bellanné‐Chantelot et al. ([2004](#mgg3962-bib-0004){ref-type="ref"})                                        
  *NEUROD1*          c.693C \> G                                               p.Tyr231Ter                                              Exon 2             *NEUROD1*‐1   P                                                                                                            This study
  *CEL*              c.71C \> T                                                p.Ala24Val                                               Exon 1             *CEL*‐1       U.S                                                                                                          This study[c](#mgg3962-note-0015){ref-type="fn"}
  c.305A \> C        p.Asp102Ala                                               Exon 3                                                   *CEL*‐2            U.S           This study                                                                                                   
  c.481G \> A        p.Val161Met                                               Exon 4                                                   *CEL*‐3            U.S           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  c.796A \> G        p.Lys266Glu                                               Exon 7                                                   D1                 U.S           This study                                                                                                   
  c.2152C \> A       p.Pro718Thr                                               Exon 11                                                  *CEL*‐4            L.B           Johansen et al. ([2014](#mgg3962-bib-0043){ref-type="ref"})                                                  
  *INS*              c.17G \> A                                                p.Arg6His                                                Exon 1             *INS*‐1       U.S                                                                                                          Meur et al. ([2010](#mgg3962-bib-0057){ref-type="ref"})
  c.65delC           p.Ala23Glnfs\*3                                           Exon 2                                                   *INS*‐2            P             This study                                                                                                   
  c.227G \> A        p.Ser76Asn                                                Exon 3                                                   *INS*‐3            L.B           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  *ABCC8*            c.157A \> T                                               p.Ser53Cys                                               Exon 2             *ABCC8*‐1     U.S                                                                                                          This study
  c.703G \> A        p.Ala235Thr                                               Exon 5                                                   *ABCC8*‐2          L.B           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  c.1688T \> A       p.Val563Asp                                               Exon 12                                                  *ABCC8*‐3          U.S           This study                                                                                                   
  c.1973G \> T       p.Gly658Val                                               Exon 14                                                  *ABCC8*‐4          U.S           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  c.2017G \> A       p.Asp673Asn                                               Exon 14                                                  *ABCC8*‐5          U.S           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  c.2473C \> T       p.Arg825Trp                                               Exon 20                                                  *ABCC8*‐6          P             Vaxillaire et al. ([2007](#mgg3962-bib-0092){ref-type="ref"})                                                
  c.3053C \> T       p.Ser1018Leu                                              Exon 25                                                  D1                 U.S           This study[c](#mgg3962-note-0015){ref-type="fn"}                                                             
  c.3440T \> G       p.Leu1147Arg                                              Exon 28                                                  *ABCC8*‐7          U.S           Gussinyer et al. ([2008](#mgg3962-bib-0040){ref-type="ref"})                                                 
  *KCNJ11*           c.286G \> A                                               p.Ala96Thr                                               Exon 1             *KCNJ11*‐1    U.S                                                                                                          Melikyan et al. ([2012](#mgg3962-bib-0076){ref-type="ref"})

RefSeq reference transcript: NM_175914.3 (*HNF4A*)/NM_000162.3 (*GCK*)/NM_000545.6 (*HNF1A*)/NM_000209.3 (*PDX1*)/NM_000458.2 (*HNF1B*)/NM_002500.3 (*NEUROD1*)/NM_001807.3 (*CEL*)/NM_000207.2 (*INS*)/NM_000352.3 (*ABCC8*)/NM_000525.3 (*KCNJ11*).

ACMG five‐tier system: B (Benign), L.B (Likely benign), P (Pathogenic), L.P (Likely pathogenic), U.S (Uncertain significance).

Reported in The Genome Aggregation Database (gnomAD).

John Wiley & Sons, Ltd

### 3.3.1. Common MODY genes {#mgg3962-sec-0015}

Among a total of 34 patients with only one candidate variant, in 47% (16/34) of them, the change was identified in one of the genes most commonly associated with MODY (three in *HNF4A*, seven in *GCK*, one in *HNF1A*, and four in *HNF1B*). Only one variant was shared by two probands (*GCK*---c.952G \> A/p.Gly318Arg).

Of these variants, three were novel (two in *HNF4A*/one in *GCK*) and 12 had been described previously. According to the ACMG/AMP guidelines, 60% (9/15) were considered pathogenic or likely pathogenic, 27% (4/15) of uncertain significance, and 13% (2/15) benign (already reported). A cosegregation analysis was possible in nine of the 16 families (Figure [2](#mgg3962-fig-0002){ref-type="fig"}).

![Pedigrees of screened MODY families with pathogenic/likely pathogenic/uncertain significance variants (A ‐ Common MODY genes, B ‐ Rare MODY genes). Square: male; Circle: female; Grey filled symbol: patient with prediabetes; Black filled symbol: patient with diabetes; Empty symbol: patient without diabetes nor prediabetes; Green filled symbol: renal cysts; Red filled symbol: pancreatic malformation; Blue filled symbol: low fecal elastase (LFE); Yellow filled symbol: LDL elevation; WT: wild‐type allele; MT: altered allele; ?/?: patient not genotyped](MGG3-7-e962-g002){#mgg3962-fig-0002}

### 3.3.2. Rare MODY genes {#mgg3962-sec-0016}

Eighteen patients (53% (18/34)) had only one candidate variant in genes that are rarely associated with MODY (two *PDX1*; one *NEUROD1*; four *CEL*; three *INS*; seven *ABCC8*; one *KCNJ11*), most of which (94% (17/18)) had an initial clinical suspicion of non‐*GCK* MODY. No variant was shared by two or more probands.

Five variants (28% (5/18)) were described for the first time in this study. The remainder (72% (13/18)) had been reported in the literature and/or mapped in genomic databases (gnomAD/ABraOM). Only four (22% (4/18)) were classified as pathogenic by ACMG/AMP, three (17% (3/18)) were likely benign, and the majority (61% (11/18)) with uncertain significance.

Only one case (3%--1/35) presented candidate variants in two genes. In this patient, two novel missense changes of uncertain significance were present in *CEL* and *ABCC8*.

Table [4](#mgg3962-tbl-0004){ref-type="table"} presents clinical follow‐up data and additional information for patients with pathogenic/probably pathogenic/uncertain significance candidate variants in rare MODY genes. Six of the 19 families were available for cosegregation analysis (Figure [2](#mgg3962-fig-0002){ref-type="fig"}).

###### 

Clinical and laboratory follow‐up data of probands with one pathogenic or uncertain significance candidate variant in a rare MODY gene

  MODY subtype                 Number of probands   Age at diagnosis of diabetes or MFH[a](#mgg3962-note-0017){ref-type="fn"} (years)[e](#mgg3962-note-0021){ref-type="fn"}   FPG[b](#mgg3962-note-0018){ref-type="fn"} (mg/dL)[e](#mgg3962-note-0021){ref-type="fn"} follow‐up   A1C[c](#mgg3962-note-0019){ref-type="fn"} (%)[e](#mgg3962-note-0021){ref-type="fn"} follow‐up   C‐peptide[d](#mgg3962-note-0020){ref-type="fn"} (ng/mL)[e](#mgg3962-note-0021){ref-type="fn"}   Typical clinical findings/diabetes complications
  ---------------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  **Pathogenic**                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  *PDX1*                       1                    14                                                                                                                        83--441                                                                                             6.8--9.2                                                                                        1.4                                                                                             Pancreatic dysgenesis/NPDR[f](#mgg3962-note-0022){ref-type="fn"}
  *NEUROD1*                    1                    20                                                                                                                        137--NA                                                                                             6.1--10.0                                                                                       1.5                                                                                             ---
  *INS*                        1                    22                                                                                                                        89--255                                                                                             6.3--9.7                                                                                        1.9                                                                                             PDR[g](#mgg3962-note-0023){ref-type="fn"}/microalbuminuria
  *ABCC8*                      1                    21                                                                                                                        90--271                                                                                             6.3--8.4                                                                                        2.3                                                                                             GSR[h](#mgg3962-note-0024){ref-type="fn"}/PDR[g](#mgg3962-note-0023){ref-type="fn"}/microalbuminuria
  **Uncertain significance**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *PDX1*                       1                    27                                                                                                                        58--193                                                                                             8.5--9.7                                                                                        1.1                                                                                             ---
  *CEL*                        4                    5--30                                                                                                                     89--400                                                                                             5.5--12.5                                                                                       1.5--2.6                                                                                        fecal elastase deficiency/dyslipidemia/microalbuminuria
  *INS*                        1                    19                                                                                                                        106--360                                                                                            10.4--13.6                                                                                      2.6                                                                                             PDR[g](#mgg3962-note-0023){ref-type="fn"}/microalbuminuria
  *KCNJ11*                     1                    20                                                                                                                        86--258                                                                                             6.4--9.4                                                                                        1.4                                                                                             ---
  *ABCC8*                      5                    12--30                                                                                                                    45--697                                                                                             5.1--13.7                                                                                       0.4--3.8                                                                                        PDR[g](#mgg3962-note-0023){ref-type="fn"}/microalbuminuria

Normal range: FPG (hexokinase) 70--99 mg/dL Minor allele frequency ; A1C (HPLC) 4.1%--6.0%; Fasting C‐peptide (chemiluminescence) 1.1--4.4 ng/mL; Microalbuminuria (immunoturbidimetry) \<14.0 mg/L; Fecal elastase (enzyme immunoassay ‐ ELISA) \>200 µg/g.

MFH, mild fasting hyperglycemia.

FPG, fasting plasma glucose.

A1C, Glycated hemoglobin.

Fasting C‐peptide: 3 years after diagnosis.

Range if available.

NPDR, nonproliferative diabetic retinopathy.

PDR, proliferative diabetic retinopathy.

GSR, good sulfonylurea response.

John Wiley & Sons, Ltd

4. DISCUSSION {#mgg3962-sec-0017}
=============

The use of a genetic panel to investigate a multilocus disease with large associated genes (without hotspots), as in MODY, is extremely advantageous in relation to the gene‐specific approach by Sanger sequencing (Colclough et al., [2014](#mgg3962-bib-0015){ref-type="ref"}; Ellard et al., [2013](#mgg3962-bib-0024){ref-type="ref"}). In recent years, some cohorts of MODY patients have been investigated using gene panels (Alkorta‐Aranburu et al., [2014](#mgg3962-bib-0001){ref-type="ref"}; Bonnefond et al., [2014](#mgg3962-bib-0009){ref-type="ref"}; Ellard et al., [2013](#mgg3962-bib-0024){ref-type="ref"}). However, these panels are not adequate for interrogating the genetic causes of MODY in many countries, such as Brazil, where the prevalence of MODY‐X (without genetic diagnosis) ranges from 46.2% to 73.9% (Furuzawa et al., [2008](#mgg3962-bib-0033){ref-type="ref"}; Maraschin et al., [2008](#mgg3962-bib-0054){ref-type="ref"}; Moises et al., [2001](#mgg3962-bib-0059){ref-type="ref"}; Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"}; Weinert et al., [2014](#mgg3962-bib-0096){ref-type="ref"}). Thus, a thorough investigation of the rarer subtypes of MODY is needed to improve their genetic diagnosis.

It is important to note that the study of rare MODY genes in a cohort preselected for the most common subtypes would contribute to the clarification of a minority of cases. A whole‐exome sequencing (WES) approach would be more efficient for clarifying not only rare MODY subtypes but also possible new genotype‐phenotype associations. In centers located in emerging countries, however, the availability of financial resources is still a limiting factor and gene‐candidate approaches are routinely used in the selection of cases for broad genomic studies, such as WES.

With this work, and with reference to a previous publication (Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"}), our group set out to investigate all the most frequent genes associated with MODY using a genetic panel in a cohort of Brazilian families. After excluding all benign, likely benign, and uncertain significance variants, besides those pathogenic/probably pathogenic ones that presented, despite their ACMG/AMP classification, some uncertain characteristic as to their definitive phenotypic association, we were able to assign a genetic cause for 12.7% (13/102) of the patients, consistent with the rate previously observed in similar studies (11%--33%) (Ellard et al., [2013](#mgg3962-bib-0024){ref-type="ref"}; Pezzilli et al., [2018](#mgg3962-bib-0067){ref-type="ref"}; Szopa et al., [2015](#mgg3962-bib-0089){ref-type="ref"}).

Forty‐three percent of the candidate genetic findings (15/35), especially in rare MODY genes, were classified as variants of uncertain significance for having insufficient or conflicting evidence in the phenotypic association. Four of these variants of uncertain significance (4/15) have an allele frequency equal to or greater than 1/15,000 in gnomAD: p.His505Asn (*HNF1A*), p.Gly76Cys (*HNF1B*), p.Arg6His (*INS*), and p.Val161Met (*CEL*), a frequency similar to the risk of type 2 diabetes alleles mapped in common MODY genes, such as *HNF1A* (Najmi et al., [2017](#mgg3962-bib-0061){ref-type="ref"}). This observation would support the notion of a complex/polygenic context of hyperglycemia, making them benign in the face of our monogenic hypothesis. Even for those variants with a populational frequency lower than expected for MODY, we cannot rule out the possibility of a spurious finding, as observed in rare nonsynonymous changes mapped in individuals without diabetes (Flannick et al., [2013](#mgg3962-bib-0028){ref-type="ref"}).

If we consider the extended genetic approach of our entire cohort (combining the 2017 (Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"})/2019 (Dotto et al., [2019](#mgg3962-bib-0019){ref-type="ref"}) studies, the present one, and added 40 MODY‐*GCK*/*HNF1A* unpublished cases (Table [S3](#mgg3962-sup-0003){ref-type="supplementary-material"})), the overall positivity (pathogenic/likely pathogenic variants) would reach 50% (89/178), where 178 is the total number of cases already investigated by Sanger sequencing or MLPA and tNGS. As a consequence of this wider analytical approach, a more precise number of cases with MODY‐X can be obtained, reaching 50% (89/178), which is still higher than the average (currently 15%--20% (Chèvre et al., [1998](#mgg3962-bib-0014){ref-type="ref"}; Fajans et al., [2001](#mgg3962-bib-0027){ref-type="ref"}; Frayling et al., [2001](#mgg3962-bib-0029){ref-type="ref"}; Frayling et al., [2003](#mgg3962-bib-0030){ref-type="ref"}; Shepherd, Sparkes, & Hattersley, [2001](#mgg3962-bib-0084){ref-type="ref"}; Shields et al., [2010](#mgg3962-bib-0085){ref-type="ref"})) reported in the literature worldwide. This number, however, may be lower since some of these unclarified cases may harbor genetic defects that were not investigated in this study (copy number variations, CNVs/large indels) or were located in regulatory and intronic regions, such as in genes that have not yet been related to the phenotype. In addition, we cannot rule out the possibility of patients who were investigated due to initial suspicion of MODY but presented another type of Diabetes Mellitus (DM) (overlapping clinical characteristics). Finally, the higher percentage of MODY‐X cases may be related to the genetically heterogeneous composition of our population, with centuries of colonization and immigration of people from dozens of countries, resulting in the observed mixing (Cardoso, de Oliveira, Paixão‐Côrtes, Castilla, & Schuler‐Faccini, [2019](#mgg3962-bib-0013){ref-type="ref"}). This characteristic may have contributed, in some way, to the existence of a different set of MODY genes that are not found in European populations from which the current set of MODY genes have been identified. Thus, the use of multiloci genomic approaches (such as WES) could uncover new MODY gene--phenotype associations in this non‐European population.

Among patients with at least one candidate variant, 46% (16/35) presented with the nonreference allele in a common MODY gene. In five of them (31%--5/16), the same gene was previously analyzed by Sanger sequencing (Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"}) (*GCK* or *HNF1A*), with a negative result (missed heterozygote) (Table [2](#mgg3962-tbl-0002){ref-type="table"}). As these five heterozygotes that Sanger sequencing missed are from our previous study (Santana et al., [2017](#mgg3962-bib-0081){ref-type="ref"}), with 35 cases (i.e., 40 true heterozygous genotypes), our missed heterozygote rate (MHR) reached 12.5% (5/40---uncalled heterozygotes/all heterozygous genotypes), consistent with the reported global MHR (9.1%--14.5%) (Quinlan & Marth, [2007](#mgg3962-bib-0070){ref-type="ref"}).

In these patients, a false‐negative result occurred due to an allelic dropout or an analytic error. Allele dropout is a rare molecular event with an estimated occurrence rate of 0.3% (Blais et al., [2015](#mgg3962-bib-0007){ref-type="ref"}). It has dependent and independent allele causal factors and has been reported during genetic research of numerous diseases (Fujimura, Northrup, Beaudet, & O'Brien, [1990](#mgg3962-bib-0032){ref-type="ref"}; Lam & Mak, [2013](#mgg3962-bib-0046){ref-type="ref"}; Schulze, Bettendorf, Maser‐gluth, Decker, & Schwabe, [1998](#mgg3962-bib-0083){ref-type="ref"}; Somerville, Sprysak, Hicks, Elyas, & Vicen‐Wyhony, [1999](#mgg3962-bib-0087){ref-type="ref"}; Wenzel et al., [2009](#mgg3962-bib-0097){ref-type="ref"}), including MODY (Ellard et al., [1999](#mgg3962-bib-0023){ref-type="ref"}; Raeder et al., [2006](#mgg3962-bib-0071){ref-type="ref"}).

The three cases observed in our cohort (*GCK‐*5/p.Gly318Arg; *GCK‐*6/p.Gly318Arg; *GCK‐*7/p.Thr326Pro) occurred in exon 8 of the *GCK*. The allele was \"lost\" during PCR due to the variant rs76323047 present at the primer annealing site (NGRL Manchester, [2019](#mgg3962-bib-0053){ref-type="ref"}), and it was recovered after oligo modification. This finding highlights an important Sanger sequencing limitation that is overcome by new sequencing technologies.

The remaining 11 common MODY cases represent the restrictions of a single‐gene approach, in addition to the application of only one molecular investigation method (Sequencing or MLPA).

Among these patients, a number of notable findings are further detailed below.

4.1. ***HNF4A*** \| **OMIM \#125850** {#mgg3962-sec-0018}
-------------------------------------

Of the three cases in which candidate variants were identified in *HNF4A*, only one comprised a previously described genetic finding (c.1321A \> G/p.Ile441Val). The family reported by Malecki et al. ([1999](#mgg3962-bib-0052){ref-type="ref"}), however, had a genotype--phenotype discrepancy (unaffected bearer) in addition to cosegregation in half of the *HNF4A* variant bearers (as well as other affected family members), of a second variant (*HNF1A*---c.872dupC/p.Gly292Argfs\*25---pathogenic). We must also point out that the *HNF4A*---c.1321A \> G/p.Ile441Val was mapped at a frequency higher (0.08%) than that expected for MODY in a local cohort of 609 healthy Brazilian elderly individuals (ABraOM) (Naslavsky et al., [2017](#mgg3962-bib-0062){ref-type="ref"}). All these findings resulted in a benign ACMG classification. Even with its isolated association with MODY is unproven, Malecki et al. ([1999](#mgg3962-bib-0052){ref-type="ref"}) noted that patients who carried both variants (*HNF1A*/*HNF4A*) presented an earlier age of diagnosis and the need for insulin therapy. Of the two remaining variants identified, neither had yet been described to be associated with the phenotype. However, one of them (c.A7G/p.Ser3Gly---uncertain significance) was mapped in a public genomic database (gnomAD) at an allele frequency lower (0.0004%) than expected for MODY. It is important to note that it was not possible to distinguish more typical MODY‐*HNF4A* characteristics, such as macrosomia, neonatal hypoglycemia (Pearson et al., [2007](#mgg3962-bib-0065){ref-type="ref"}), or good sulfonylurea response (Pearson et al., [2003](#mgg3962-bib-0066){ref-type="ref"}), in either of the two patients.

4.2. *GCK* {#mgg3962-sec-0019}
----------

Three patients with initial diagnostic suspicion of MODY‐*HNF1A* presented previously described pathogenic/probably pathogenic variants in *GCK*. The diagnostic hypothesis error occurred due to the presence of an atypical glycemic pattern and/or a good therapeutic response to sulfonylurea (probands *GCK*‐1/*GCK*‐3/*GCK*‐4---Table [2](#mgg3962-tbl-0002){ref-type="table"}). It is important to highlight that all of these patients currently control their glycemic levels by means of diet alone, demonstrating the importance of a genetic diagnosis with the correct MODY subtype identification.

4.3. *HNF1B* {#mgg3962-sec-0020}
------------

Four probands were identified with candidate changes in *HNF1B* and to our surprise, only one had initial clinical manifestations specific to this MODY subtype (multiple renal cysts and pancreas body/tail agenesis). In one of the three remaining cases, the candidate variant c.182T \> G/p.Val61Gly, which had been previously described, was disregarded at the end of its ACMG classification. Despite changes having been described in numerous cohorts (Bonnefond et al., [2014](#mgg3962-bib-0009){ref-type="ref"}; Edghill, Bingham, Ellard, & Hattersley, [2006](#mgg3962-bib-0021){ref-type="ref"}; Faguer et al., [2011](#mgg3962-bib-0025){ref-type="ref"}; Granberg et al., [2012](#mgg3962-bib-0039){ref-type="ref"}; Hoskins et al., [2007](#mgg3962-bib-0041){ref-type="ref"}; Oram et al., [2010](#mgg3962-bib-0063){ref-type="ref"}), in patients with DM and renal/pancreatic/genitourinary dysgenesis, a functional study (Granberg et al., [2012](#mgg3962-bib-0039){ref-type="ref"}) showed no difference in comparison between the variant and its wild‐type allele. In addition, it was mapped at a high frequency for MODY in both the global (gnomAD) and local Brazilian cohorts (ABraOM), contributing to benign ACMG categorization. Although the last two cases initially did not show evident pancreatic/extra pancreatic manifestations, a phenotypic correlation with the *HNF1B* genetic finding was established. The proband bearer of the described likely pathogenic variant c.884G \> A/p.Arg295His was investigated, after genetic testing, for the presence of typical dysgenesis. Magnetic resonance imaging (MRI) demonstrated pancreas body/tail agenesis in addition to the presence of renal cysts. Despite this finding, the patient had normal renal/liver function in addition to normomagnesemia. Finally, in the bearer of the described uncertain significance variant c.226G \> T/p.Gly76Cys, a pancreas diffuse volume reduction was found after performing a CT scan. Additionally, an elevation of hepatic enzymes was observed without apparent functional impairment.

It is important to highlight how the use of a gene panel was a decisive factor for the correct identification of the MODY subtype in these cases. The genetic diagnoses of these patients could have been missed due to the absence of typical clinical findings during the first evaluation. In addition, because large deletions are a frequent finding in MODY‐*HNF1B* (in approximately 50% or more of the cases) (Edghill et al., [2013](#mgg3962-bib-0022){ref-type="ref"}), the initial approach aimed to identify CNVs in the gene. Our three cases presented missense variants.

Over half (53% (18/34)) of the cases identified with only one candidate variant showed a change in a rare MODY gene, evidencing the importance of the investigating rare MODY subtypes.

4.4. ***PDX1*** \| **OMIM \#606392** {#mgg3962-sec-0021}
------------------------------------

In addition to the family with a new phenotype already described by our group (Caetano et al., [2018](#mgg3962-bib-0011){ref-type="ref"}), a second proband was identified with the uncertain significance variant c.664G \> A/p.Glu222Lys. Its population frequency, however, was high in the local control cohort (ABraOM), contributing to its ACMG classification. A familial cosegregation analysis, in addition to an investigation of possible pancreatic malformations (Caetano et al., [2018](#mgg3962-bib-0011){ref-type="ref"}), will help to determine the pathogenicity of the variant.

4.5. ***NEUROD1*** \| **OMIM \#606394** {#mgg3962-sec-0022}
---------------------------------------

The only nonsense modification in the cohort, the novel pathogenic c.693C \> G/p.Tyr231Ter, was present in *NEUROD1*. Heterozygous variants in this gene are a rare cause of MODY, with a notable incomplete penetrance among the members of reported families (Demirbilek et al., [2018](#mgg3962-bib-0018){ref-type="ref"}). Extrapancreatic manifestations have already been described, such as neurological abnormalities in homozygous individuals (permanent neonatal diabetes mellitus) (Demirbilek et al., [2018](#mgg3962-bib-0018){ref-type="ref"}; Rubio‐Cabezas et al., [2010](#mgg3962-bib-0079){ref-type="ref"}). Our patients did not present any other atypical clinical findings, besides the classic MODY remarks. Cosegregation analysis could help to reinforce the final interpretation of this variant, which compromises the NEUROD1 transactivation domain (Rubio‐Cabezas et al., [2010](#mgg3962-bib-0079){ref-type="ref"}).

4.6. ***CEL*** \| **OMIM \#609812** {#mgg3962-sec-0023}
-----------------------------------

*CEL* was the second, among rare MODY genes, with the largest number of candidate variants: five with uncertain significance missense changes. None of them had been previously described to be associated with the phenotype, and one was identified in one case with another candidate variant (*ABCC8*). Approximately, half of these *CEL* variants were mapped in the gnomAD consortium at an allele frequency lower than expected for MODY, which would not initially discard them from a probable association with the phenotype. The *CEL* analysis by first/second‐generation sequencing constituted a challenge due to its structure. The presence of its in‐tandem pseudogene (*CELP*) (Madeyski, Lidberg, Bjursell, & Nilsson, [1998](#mgg3962-bib-0051){ref-type="ref"}) hindered the precise read alignment and variant calling process. In addition, it was extremely polymorphic and had a variable number of tandem repetitions (VNTR) in exon 11. Segments of approximately 33 bp may be repeated 7--23 times in the general population (Torsvik et al., [2010](#mgg3962-bib-0091){ref-type="ref"}). Until now, only frameshift mutational events in this region were associated with a monogenic diabetes‐pancreatic exocrine dysfunction syndrome with typical fecal elastase deficiency (FED), mild abdominal pain, and loose stools (Ræder et al., [2006](#mgg3962-bib-0072){ref-type="ref"}; Torsvik et al., [2010](#mgg3962-bib-0091){ref-type="ref"}). All five candidate variants identified in our cohort were missense, and only one was located in exon 11. In addition, none of the patients showed any clinical signs of exocrine pancreatic deficiency. However, one of the *CEL*‐2 relatives had low fecal elastase. The proband of this family also showed a reduction in the volume of the pancreas on the MRI and microalbuminuria. Interestingly, three patients (variants in exons 1, 3, and 11) showed Low‐density lipoprotein elevations, one of which was diagnosed with aortic atheromatosis. A fraction of the CEL lipase has already been detected in the plasma, suggesting its interaction with cholesterol molecules and lipoproteins (Bengtsson‐Ellmark et al., [2004](#mgg3962-bib-0006){ref-type="ref"}; Caillol et al., [1997](#mgg3962-bib-0012){ref-type="ref"}). Although these variants may influence the lipid profile of these patients, their definitive association with MODY could not yet be established in our cohort. An extension of cosegregation analysis in these families, with the exception of that already performed with the *CEL*‐2 proband, would help to determine the degree of pathogenicity of these variants.

4.7. ***INS*** \| **OMIM \#613370** {#mgg3962-sec-0024}
-----------------------------------

With the exception of the probably benign and uncertain significance *INS* variants, only one (1/3) was classified as pathogenic according to ACMG/AMP guidelines. The novel heterozygous frameshift c.65delC/p.Ala23Glnfs\*3 truncates the protein in preproinsulin signal peptide (Liu et al., [2015](#mgg3962-bib-0049){ref-type="ref"}). Different molecular mechanisms (and inheritance models) have been previously described for the phenotypes caused by *INS* variants, that is, processing defects in preproinsulin, proinsulin misfolding, ER stress, and impaired insulin binding to its receptor (Liu et al., [2015](#mgg3962-bib-0049){ref-type="ref"}). Since the *INS* does not suffer from haploinsufficiency, as previously demonstrated experimentally using knockout mice (Leroux et al., [2001](#mgg3962-bib-0048){ref-type="ref"}), the molecular pathogenesis related to the dominant inheritance model is attributed to the mutated protein cytotoxicity (Oyadomari et al., [2002](#mgg3962-bib-0064){ref-type="ref"}; Ron, [2002](#mgg3962-bib-0078){ref-type="ref"}; Wang et al., [1999](#mgg3962-bib-0095){ref-type="ref"}), rather than insulin deficiency (recessive inheritance) (Garin et al., [2010](#mgg3962-bib-0035){ref-type="ref"}; Raile et al., [2011](#mgg3962-bib-0074){ref-type="ref"}). Our variant c.65delC/p.Ala23Glnfs\*3 is predicted to undergo nonsense‐mediated decay (NMD) due to the premature termination codon (PTC) at amino acid position 26. Thus, no protein would be generated and there is no toxic gain of function effect. Among the dominant‐inheritance *INS* variants already reported, there is only one null type: a heterozygous de novo stop‐gain p.Tyr108Ter. The variant was identified in a permanent neonatal diabetes patient (Colombo et al., [2008](#mgg3962-bib-0016){ref-type="ref"}). Functional evidence suggests that the truncated protein is translated, and NMD is not involved, leading to a proinsulin misfolding with ER stress, in addition to improper disulfide bonds with little or no insulin secretion. In this case, an NMD escaping was possible due to PTC position (within the last exon of a gene) (Kurosaki & Maquat, [2016](#mgg3962-bib-0045){ref-type="ref"}; Nagy & Maquat, [1998](#mgg3962-bib-0060){ref-type="ref"}). This would apply to any PTC occurring at amino acid position 43 onwards in the *INS*. Despite the ACMG/AMP classification, so far, there is no functional evidence to suggest that c.65delC/p.Ala23Glnfs\*3 will escape NMD. Hence, the role of this *INS* variant in heterozygous state in diabetes phenotype remains to be determined.

4.8. *ABCC8* \| **OMIM \*600509** {#mgg3962-sec-0025}
---------------------------------

*ABCC8* had the largest number of candidate changes, with eight in total, among which one was in a patient with another candidate variant (*CEL*). Only one of the eight *ABCC8* variants could be classified as pathogenic, the missense variant p.Arg825Trp/p.R825W, which was previously associated with MODY in a French subject (Riveline et al., [2012](#mgg3962-bib-0076){ref-type="ref"}), in a study demonstrating the impairment of its function (de Wet et al., [2008](#mgg3962-bib-0017){ref-type="ref"}), and which almost completely segregated with the phenotype in our family. The only observed genotype/phenotype discrepancy was most likely due to incomplete penetrance, as already described (Klupa et al., [2009](#mgg3962-bib-0044){ref-type="ref"}). It is important to note that the proband was diabetic for more than 30 years and always controlled his hyperglycemia with low doses of sulfonylurea. This good therapeutic response is classically observed in neonatal diabetes cases due to sulfonylurea receptor 1 (SUR1) (encoded by *ABCC8*) pathogenic variants (Rafiq et al., [2008](#mgg3962-bib-0073){ref-type="ref"}). Finally, an atypical finding caught our attention. The *ABCC8*‐7 proband, a typical initial suspicion of MODY‐*HNF1B* (multiple bilateral renal cysts associated with DM), presented an already described uncertain significance variant in *ABCC8*. Curiously, the change p.Leu1147Arg/p.L1147R was reported in compound heterozygosity associated with neonatal diabetes (OMIM \#606176) (Alkorta‐Aranburu et al., [2014](#mgg3962-bib-0001){ref-type="ref"}) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI) (OMIM \#256450) (evolving to glucose intolerance) (Gussinyer et al., [2008](#mgg3962-bib-0040){ref-type="ref"}). Our patient did not present any typical neonatal characteristics of the previously mentioned phenotypes. We believe that cosegregation analysis could help to clarify the role of this heterozygosis variant in this family. It should be noted, however, that great clinical heterogeneity has already been described with *ABCC8* variants, in the most diverse forms of inheritance (Klupa et al., [2009](#mgg3962-bib-0044){ref-type="ref"}). In addition, the presence of renal cysts may only be an incidental finding unrelated to DM.

4.9. ***KCNJ11*** \| **OMIM \#616329** {#mgg3962-sec-0026}
--------------------------------------

The only *KCNJ11* candidate variant p.Ala96Thr was classified as uncertain significance and reported twice, namely, in homozygosis (Melikyan et al., [2012](#mgg3962-bib-0056){ref-type="ref"}) and in an apparent focal case (somatic loss of heterozygosity (LOH)) (Mohnike et al., [2014](#mgg3962-bib-0058){ref-type="ref"}) associated with congenital hyperinsulinism. A detailed clinical report about relative carriers is not available. A heterozygous father was cited in the focal case study; however, hyperglycemia was not mentioned (only congenital hyperinsulinism discarded). In our family, six members were screened. Genotype--phenotype discrepancy was observed in one individual. The unaffected proband\'s granddaughter carried the variant without any glycemic alteration. As with *ABCC8*, also a subunit encoder of the pancreatic beta‐cell ATP‐sensitive channel, diverse phenotypes with distinct inheritance patterns have been previously associated with *KCNJ11* (neonatal diabetes \| OMIM \#606176 (Gloyn et al., [2004](#mgg3962-bib-0038){ref-type="ref"}), MODY (Bonnefond et al., [2012](#mgg3962-bib-0008){ref-type="ref"}), and hyperinsulinemic hypoglycemia \| OMIM \#601820 (Thomas, Ye, & Lightner, [1996](#mgg3962-bib-0090){ref-type="ref"})). This genetic‐molecular spectrum often hinders the interpretation of mono/biallelic carriers, as in the *KCNJ11* p.Arg34Cys variant and transient neonatal diabetes/congenital hyperinsulinism, which is subsequently clarified using expression studies (Snider et al., [2013](#mgg3962-bib-0086){ref-type="ref"}).

5. CONCLUSIONS {#mgg3962-sec-0027}
==============

The gene panel used in this study allowed for the simultaneous analysis of 11 genes frequently associated with MODY for the first time in a Brazilian cohort of genetically unclarified cases. This approach allowed for the detection of variants in genes not usually studied for the genetic diagnosis of MODY at most Brazilian medical centers, contributing to the identification of rare subtypes. As a result, the large percentage of local \"MODY‐X\" cases commonly reported was reduced.

The identification of rare MODY subtypes is important to expand on existing reports. Given the small number of subjects and the often‐great phenotypic variability (even intrafamily), establishing a typical clinical laboratory pattern, in contrast to the established effects of the most prevalent ones, is challenging.

Therefore, the use of multiloci genomic approaches (such as targeted sequencing or WES) is of fundamental importance, allowing for the genetic diagnosis of typical unclarified cases. Moreover, it allows for a better clinical, therapeutic, and prognostic characterization of rare phenotypes, thus contributing to our understanding of the basic pathogenesis of common diseases.
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